PLN-101095 pivots Pliant into ICI-resistant oncology; 2027 Phase 1b interim data will test whether integrin blockade can restore checkpoint sensitivity

Bull

A positive readout would show confirmed objective responses (ORs) in multiple cohorts, with the IFN-γ signal seen in Phase 1 replicating at scale — e.g., confirmed response rates of 20–30%+ in ICI-refractory patients, consistent with the 4/10 responder signal from Phase 1. This would validate integrin blockade as a mechanistically credible approach to reversing ICI resistance, likely triggering expansion cohorts, partnership interest, and a material re-rating of the pipeline.

Bear

The most likely failure modes are loss of the Phase 1 response signal at larger sample size — Phase 1's 4/10 result may reflect patient selection bias or statistical noise rather than a reproducible biological effect. Alternatively, responses may be transient without durable disease control, or the IFN-γ biomarker may not predict response in the more standardized FORTIFY patient selection, leaving no efficacy signal to advance.